ActiTrexx GmbH is a spin-off from the University Medical Center Mainz and was founded in 2020. The company develops ATreg, a cell therapy based on activated regulatory T cells that are stimulated using a proprietary process, for the treatment of transplant rejection, primarily in the field of stem cell transplantation, and autoimmune disorders. The product candidate is in advanced preclinical development and showed unique efficacy in the treatment of GvHD in relevant proof-of-concept studies.

ActiTrexx is founded by a strong and diverse management team comprised of executives with multi-year experience (> 80 years) in different functions and fields in academia, biotechnology and pharmaceutical companies. Our team will be supported and complemented by adding experienced managers, a strong network of collaborators, advisors and key opinion leaders in the field of immunology and hematology.


HTGF Investment ActiTrexx

Newly founded biotech company ActiTrexx receives funding of € 3.5 million to develop cell therapy against transplant rejection ActiTrexx GmbH, a new biotech spin-off from the University Medical Center Mainz, Germany, has successfully closed its Series A…

Info & Contact


ActiTrexx GmbH
c/o Universitätsklinikum Mainz
Langenbeckstr. 1, 55131 Mainz

In portfolio

25. Feb 2021